Androgen receptor (AR) is the most relevant signaling pathway in prostate cancer, and is presently considered a significant drug target, since its inhibition has demonstrated to be important for prostate cancer prevention and treatment [106,107,108]. Here, AR is linked to prostate carcinoma.